GNRH2 多态性在男性前列腺癌治疗与雄激素缺乏疗法治疗的男性
Tristan M Sissung1, Sarah Lochrin1, Tyler Liu1
1Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Anticancer research
|August 30, 2023
概括
性腺激素释放激素2 (GNRH2) 在前列腺组织中存在. 然而,GNRH2 A16V变异不会影响前列腺癌患者的抗雄激素缺乏治疗结果或存活率.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 淋巴激素释放激素2 (GNRH2) 是一种在中枢神经系统和外围组织中发现的类激素.
- 一种特定的变异,GNRH2 A16V (rs6051545),与水平的增加有关.
- 在前列腺癌中,GNRH2及其变异的临床意义在很大程度上仍未被探索.
研究的目的:
- 为了研究GNRH2在各种前列腺组织类型中的表达.
- 确定GNRH2 A16V变异是否影响接受雄激素缺乏治疗 (ADT) 的患者无进展生存 (PFS) 和整体生存 (OS).
主要方法:
- 用免疫光学评估前列腺组织微阵列中的GNRH2表达.
- 在接受ADT的131名前列腺癌患者中进行了GNRH2 A16V变异的基因型鉴定.
- 无进展生存 (PFS) 和整体生存 (OS) 在变种和野生类型基因型的患者之间进行了比较.
主要成果:
- 在所有检查的前列腺组织 (正常的,多质的,癌症的) 中检测到GNRH2表达,而与格里森等级或疾病阶段没有显著的相关性.
- GNRH2 A16V基因型没有与PFS或OS相关.
- 格里森得分和确定的局部治疗是PFS的显著预测因素,而年龄和格里森得分预测了OS.
结论:
- GNRH2在前列腺组织中无处不在表达,无论病理状态如何.
- 在接受ADT的前列腺癌患者中,GNRH2 A16V变异并不是治疗反应或生存的决定因素.
相关概念视频
The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K
Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K
Transducer Mechanism: Nuclear Receptors
1.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K


